期刊
CURRENT ALLERGY AND ASTHMA REPORTS
卷 11, 期 1, 页码 7-11出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11882-010-0153-8
关键词
Asthma; Interleukin-33; ST2; Interleukin-1 family
资金
- National Institutes of Health
- Genentech
- Merck Co.
- American Academy of Allergy, Asthma, and Immunology
- American College of Allergy, Asthma, and Immunology
- World Allergy Organization
In complex disorders such as asthma and allergic disease, the goal for developing disease-modifying biotherapeutics is to find a target that is a central instigator of immunologic activity. Interleukin (IL)-33 seems to be such a molecule, as it is one of the earliest-released signaling molecules following epithelial damage and can orchestrate the recruitment and activation of the cells responsible for disease. Unregulated IL-33 activity leads to activation of T-helper type 2 cells, mast cells, dendritic cells, eosinophils, and basophils, ultimately leading to increased expression of cytokines and chemokines that define the disease. As such, IL-33 is an attractive candidate for therapeutic intervention with the goal of ameliorating disease. This review focuses on the role of IL-33 in promoting and maintaining the asthma phenotype.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据